KH-1814
Exosome Therapy for Neurodegenerative Diseases
The KH-1814 project aims to develop an innovative and advanced new treatment for neurodegenerative diseases, which affect millions of people across the globe, by utilizing specialized cells derived from perinatal tissues. This approach holds significant promise for improving patient outcomes and advancing medical research in this challenging field.
KH-1814 specifically targets several key pathological processes involved in neurodegenerative disorders, including neuroinflammation, oxidative stress, and the degeneration of dopaminergic neurons.
KH-1814 is an innovative exosome therapy that offers hope by not only alleviating the debilitating symptoms of neurodegenerative conditions but also holds the potential to partially reverse some of the underlying damaging effects caused by these diseases. Through the continued advancement and refinement of this cutting-edge technology, the project aims to address a critical gap in existing treatment options and to significantly improve long-term public health outcomes for individuals affected by neurodegenerative disorders, as well as potentially other related neurological conditions.
—Mercedes F. Kweh, Co-Founder & CEO